Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Allergen immunotherapy for the prevention of allergy : a systematic review and meta-analysis. / Kristiansen, Maria; Dhami, Sangeeta; Netuveli, Gopal; Halken, Susanne; Antonella, Muraro; Roberts, Graham; Larenas-Linnemann, Desiree; Calderón, Moises A.; Penagos, Martin; Du Toit, George; Ansotegui, Ignacio J.; Kleine-Tebbe, Jörg; Lau, Susanne; Matricardi, Paolo Maria; Pajno, Giovanni; Papadopoulos, Nikolaos G.; Pfaar, Oliver; Ryan, Dermot; Santos, Alexandra F. ; Timmermanns, Frans; Wahn, Ulrich; Sheikh, Aziz.

I: Pediatric Allergy and Immunology, Bind 28, Nr. 1, 02.2017, s. 18–29.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kristiansen, M, Dhami, S, Netuveli, G, Halken, S, Antonella, M, Roberts, G, Larenas-Linnemann, D, Calderón, MA, Penagos, M, Du Toit, G, Ansotegui, IJ, Kleine-Tebbe, J, Lau, S, Matricardi, PM, Pajno, G, Papadopoulos, NG, Pfaar, O, Ryan, D, Santos, AF, Timmermanns, F, Wahn, U & Sheikh, A 2017, 'Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis', Pediatric Allergy and Immunology, bind 28, nr. 1, s. 18–29. https://doi.org/10.1111/pai.12661

APA

Kristiansen, M., Dhami, S., Netuveli, G., Halken, S., Antonella, M., Roberts, G., Larenas-Linnemann, D., Calderón, M. A., Penagos, M., Du Toit, G., Ansotegui, I. J., Kleine-Tebbe, J., Lau, S., Matricardi, P. M., Pajno, G., Papadopoulos, N. G., Pfaar, O., Ryan, D., Santos, A. F., ... Sheikh, A. (2017). Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatric Allergy and Immunology, 28(1), 18–29. https://doi.org/10.1111/pai.12661

Vancouver

Kristiansen M, Dhami S, Netuveli G, Halken S, Antonella M, Roberts G o.a. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatric Allergy and Immunology. 2017 feb;28(1):18–29. https://doi.org/10.1111/pai.12661

Author

Kristiansen, Maria ; Dhami, Sangeeta ; Netuveli, Gopal ; Halken, Susanne ; Antonella, Muraro ; Roberts, Graham ; Larenas-Linnemann, Desiree ; Calderón, Moises A. ; Penagos, Martin ; Du Toit, George ; Ansotegui, Ignacio J. ; Kleine-Tebbe, Jörg ; Lau, Susanne ; Matricardi, Paolo Maria ; Pajno, Giovanni ; Papadopoulos, Nikolaos G. ; Pfaar, Oliver ; Ryan, Dermot ; Santos, Alexandra F. ; Timmermanns, Frans ; Wahn, Ulrich ; Sheikh, Aziz. / Allergen immunotherapy for the prevention of allergy : a systematic review and meta-analysis. I: Pediatric Allergy and Immunology. 2017 ; Bind 28, Nr. 1. s. 18–29.

Bibtex

@article{b0cab02dcbc84c7bad637b68df861844,
title = "Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis",
abstract = "Background: There is a need to establish the effectiveness, cost-effectiveness and safety of allergen immunotherapy (AIT) for the prevention of allergic disease.Methods:Two reviewers independently screened nine international biomedical databases. Studies were quantitatively synthesized using random-effects meta-analyses.Results: 32 studies satisfied the inclusion criteria. Overall, meta-analysis found no conclusive evidence that AIT reduced the risk of developing a first allergic disease over the short-term (RR=0.30; 95%CI 0.04 to 2.09) and no randomized controlled evidence was found in relation to its longer-term effects for this outcome. There was however a reduction in the short-term risk of those with allergic rhinitis developing asthma (RR=0.40; 95%CI 0.29 to 0.54), with this finding being robust to a pre-specified sensitivity analysis. We found inconclusive evidence that this benefit was maintained over the longer-term: RR=0.62; 95%CI 0.31 to 1.23. There was evidence that the risk of new sensitization was reduced over the short-term, but this was not confirmed in the sensitivity analysis: RR=0.72; 95%CI 0.24 to 2.18. There was no clear evidence of any longer-term reduction in the risk of sensitization: RR=0.47; 95%CI 0.08 to 2.77. AIT appeared to have an acceptable side-effect profile.Conclusions: AIT did not result in a statistically significant reduction in the risk of developing a first allergic disease. There was however evidence of a reduced short-term risk of developing asthma in those with allergic rhinitis, but it is unclear whether this benefit was maintained over the longer-term. We are unable to comment on the cost-effectiveness of AIT.",
keywords = "Faculty of Health and Medical Sciences, Immunotherapy, Allergy and Immunology, Systematic review, Meta-analysis",
author = "Maria Kristiansen and Sangeeta Dhami and Gopal Netuveli and Susanne Halken and Muraro Antonella and Graham Roberts and Desiree Larenas-Linnemann and Calder{\'o}n, {Moises A.} and Martin Penagos and {Du Toit}, George and Ansotegui, {Ignacio J.} and J{\"o}rg Kleine-Tebbe and Susanne Lau and Matricardi, {Paolo Maria} and Giovanni Pajno and Papadopoulos, {Nikolaos G.} and Oliver Pfaar and Dermot Ryan and Santos, {Alexandra F.} and Frans Timmermanns and Ulrich Wahn and Aziz Sheikh",
year = "2017",
month = feb,
doi = "10.1111/pai.12661",
language = "English",
volume = "28",
pages = "18–29",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Allergen immunotherapy for the prevention of allergy

T2 - a systematic review and meta-analysis

AU - Kristiansen, Maria

AU - Dhami, Sangeeta

AU - Netuveli, Gopal

AU - Halken, Susanne

AU - Antonella, Muraro

AU - Roberts, Graham

AU - Larenas-Linnemann, Desiree

AU - Calderón, Moises A.

AU - Penagos, Martin

AU - Du Toit, George

AU - Ansotegui, Ignacio J.

AU - Kleine-Tebbe, Jörg

AU - Lau, Susanne

AU - Matricardi, Paolo Maria

AU - Pajno, Giovanni

AU - Papadopoulos, Nikolaos G.

AU - Pfaar, Oliver

AU - Ryan, Dermot

AU - Santos, Alexandra F.

AU - Timmermanns, Frans

AU - Wahn, Ulrich

AU - Sheikh, Aziz

PY - 2017/2

Y1 - 2017/2

N2 - Background: There is a need to establish the effectiveness, cost-effectiveness and safety of allergen immunotherapy (AIT) for the prevention of allergic disease.Methods:Two reviewers independently screened nine international biomedical databases. Studies were quantitatively synthesized using random-effects meta-analyses.Results: 32 studies satisfied the inclusion criteria. Overall, meta-analysis found no conclusive evidence that AIT reduced the risk of developing a first allergic disease over the short-term (RR=0.30; 95%CI 0.04 to 2.09) and no randomized controlled evidence was found in relation to its longer-term effects for this outcome. There was however a reduction in the short-term risk of those with allergic rhinitis developing asthma (RR=0.40; 95%CI 0.29 to 0.54), with this finding being robust to a pre-specified sensitivity analysis. We found inconclusive evidence that this benefit was maintained over the longer-term: RR=0.62; 95%CI 0.31 to 1.23. There was evidence that the risk of new sensitization was reduced over the short-term, but this was not confirmed in the sensitivity analysis: RR=0.72; 95%CI 0.24 to 2.18. There was no clear evidence of any longer-term reduction in the risk of sensitization: RR=0.47; 95%CI 0.08 to 2.77. AIT appeared to have an acceptable side-effect profile.Conclusions: AIT did not result in a statistically significant reduction in the risk of developing a first allergic disease. There was however evidence of a reduced short-term risk of developing asthma in those with allergic rhinitis, but it is unclear whether this benefit was maintained over the longer-term. We are unable to comment on the cost-effectiveness of AIT.

AB - Background: There is a need to establish the effectiveness, cost-effectiveness and safety of allergen immunotherapy (AIT) for the prevention of allergic disease.Methods:Two reviewers independently screened nine international biomedical databases. Studies were quantitatively synthesized using random-effects meta-analyses.Results: 32 studies satisfied the inclusion criteria. Overall, meta-analysis found no conclusive evidence that AIT reduced the risk of developing a first allergic disease over the short-term (RR=0.30; 95%CI 0.04 to 2.09) and no randomized controlled evidence was found in relation to its longer-term effects for this outcome. There was however a reduction in the short-term risk of those with allergic rhinitis developing asthma (RR=0.40; 95%CI 0.29 to 0.54), with this finding being robust to a pre-specified sensitivity analysis. We found inconclusive evidence that this benefit was maintained over the longer-term: RR=0.62; 95%CI 0.31 to 1.23. There was evidence that the risk of new sensitization was reduced over the short-term, but this was not confirmed in the sensitivity analysis: RR=0.72; 95%CI 0.24 to 2.18. There was no clear evidence of any longer-term reduction in the risk of sensitization: RR=0.47; 95%CI 0.08 to 2.77. AIT appeared to have an acceptable side-effect profile.Conclusions: AIT did not result in a statistically significant reduction in the risk of developing a first allergic disease. There was however evidence of a reduced short-term risk of developing asthma in those with allergic rhinitis, but it is unclear whether this benefit was maintained over the longer-term. We are unable to comment on the cost-effectiveness of AIT.

KW - Faculty of Health and Medical Sciences

KW - Immunotherapy

KW - Allergy and Immunology

KW - Systematic review

KW - Meta-analysis

U2 - 10.1111/pai.12661

DO - 10.1111/pai.12661

M3 - Journal article

C2 - 27653623

VL - 28

SP - 18

EP - 29

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 1

ER -

ID: 166059175